Skip to main content
35261 search results for:

Cancer Immunotherapy 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 01-12-2024 | ReviewPaper

    Neutrophils in Cancer immunotherapy: friends or foes?

    Neutrophils play a Janus-faced role in the complex landscape of cancer pathogenesis and immunotherapy. As immune defense cells, neutrophils release toxic substances, including reactive oxygen species and matrix metalloproteinase 9, within the …

  2. Free for a limited time 01-06-2024 | Head and Neck Cancer | ReviewPaper

    Research progress of immunotherapy for advanced head and neck cancer

    Surgery, radiotherapy, and chemotherapy are the primary treatments for advanced head and neck cancer, but checkpoint inhibition has recently shown promise. Delve into the efficacy and safety data for the key agents.

  3. Open Access 01-12-2024 | Cancer Immunotherapy | ReviewPaper

    CD8+ T cell-based cancer immunotherapy

    The immune system in humans is a defense department against both exogenous and endogenous hazards, where CD8+ T cells play a crucial role in opposing pathological threats. Various immunotherapies based on CD8+ T cells have emerged in recent …

  4. Open Access 01-12-2024 | Respiratory Microbiota | ReviewPaper

    Critical role of the gut microbiota in immune responses and cancer immunotherapy

    The gut microbiota plays a critical role in the progression of human diseases, especially cancer. In recent decades, there has been accumulating evidence of the connections between the gut microbiota and cancer immunotherapy. Therefore …

  5. Open Access 10-05-2024 | OriginalPaper

    Toxicity in Older Patients with Cancer Receiving Immunotherapy: An Observational Study

    Cancer is highly prevalent in old age and it is estimated that 55% of new cases are diagnosed in people aged over 65 years [ 1 ]. Older patients are a heterogeneous group with a large variation in geriatric problems such as impaired cognitive and …

  6. Open Access 03-05-2024 | Cancer Immunotherapy | Online First

    Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges

    Immune checkpoint inhibitor (ICI)-based therapy has made an unprecedented impact on survival benefit for a subset of cancer patients; however, only a subset of cancer patients is benefiting from ICI therapy if all cancer types are considered. With …

  7. Open Access 01-12-2024 | Breast Cancer | OriginalPaper

    Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer

    Breast cancer is the most common cancer, and the second leading cause of cancer death in women [ 1 ]. Triple negative breast cancer (Her2 neg , estrogen receptor neg , progesterone receptor neg ) has the lowest survival rate of any breast cancer

  8. Open Access 01-12-2024 | Cancer Immunotherapy | Letter

    The association of ROS1 mutation with cancer immunity and its impact on the efficacy of pan-cancer immunotherapy

  9. 13-05-2024 | Computed Tomography | Online First

    Deep Learning-Based Detect-Then-Track Pipeline for Treatment Outcome Assessments in Immunotherapy-Treated Liver Cancer

    Accurate treatment outcome assessment is crucial in clinical trials. However, due to the image-reading subjectivity, there exist discrepancies among different radiologists. The situation is common in liver cancer due to the complexity of abdominal …

  10. Open Access 01-12-2024 | Breast Cancer | ReviewPaper

    Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer

    Breast cancer, the most frequent female malignancy, is often curable when detected at an early stage. The treatment of metastatic breast cancer is more challenging and may be unresponsive to conventional therapy. Immunotherapy is crucial for …

  11. 22-04-2024 | Gastric Cancer | Online First

    Biomarker-oriented chemo-immunotherapy for advanced gastric cancer

    The biomarker-oriented chemo-immunotherapy is useful and promising in the development of new anticancer agents, since the responders can be enriched by selecting patients with biomarkers. Compared to colorectal and lung cancers, the development of …

  12. Open Access 01-12-2024 | SCLC | Letter

    DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy

    DLL3 acts as an inhibitory ligand that downregulates Notch signaling and is upregulated by ASCL1, a transcription factor prevalent in the small-cell lung cancer (SCLC) subtype SCLC-A. Currently, the therapeutic strategies targeting DLL3 are …

  13. Open Access 01-12-2024 | Cancer Immunotherapy | OriginalPaper

    GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy

    The quality of the immune system is based on a precise balance between activating and inhibiting signals to maintain immune homeostasis. Immune checkpoints act as inhibiting signals whose role is to prevent the immune system from overactivation …

  14. 01-05-2024 | Cancer Immunotherapy | ReviewPaper

    Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy

    Drug repositioning or repurposing has gained worldwide attention as a plausible way to search for novel molecules for the treatment of particular diseases or disorders. Drug repurposing essentially refers to uncovering approved or failed compounds …

  15. Open Access 01-07-2024 | Gastric Cancer | OriginalPaper

    GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration

    Gastric cancer (GC) is one of the most prevalent digestive malignancies, ranking fifth in terms of tumor morbidity and fourth in terms of mortality [ 1 ]. Its incidence is particularly high in East Asia [ 2 ]. Although reports indicate a decline in …

  16. Open Access 01-12-2024 | Cancer Immunotherapy | ReviewPaper

    Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy

    Cancer immunotherapy and vaccine development have significantly improved the fight against cancers. Despite these advancements, challenges remain, particularly in the clinical delivery of immunomodulatory compounds. The tumor microenvironment …

  17. Open Access 01-06-2024 | Gastric Cancer | OriginalPaper

    New genetic insights into immunotherapy outcomes in gastric cancer via single-cell RNA sequencing and random forest model

    Gastric cancer is universally recognized as a highly fatal malignancy, contributing significantly to global cancer mortality rates [ 1 – 3 ]. Annually, it is responsible for the diagnosis of hundreds of thousands of individuals, frequently at …

  18. Open Access 01-12-2024 | NSCLC | OriginalPaper

    Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)

    Besides programmed death ligand 1 (PD-L1) expression, rapid, cost-effective and validated scores or models are critical for the prognosis and prediction of patients received immune checkpoint inhibitors (ICIs). In this retrospective study, 182 …

  19. Open Access 01-12-2024 | Checkpoint Inhibitors | Letter

    Mutation of neurotrophic tyrosine receptor kinase can promote pan-cancer immunity and the efficacy of immunotherapy

    The Neurotrophic tyrosine receptor kinase (NTRK) family plays important roles in tumor progression and is involved in tumor immunogenicity. Here, we conducted a comprehensive bioinformatic and clinical analysis to investigate the characteristics …

  20. Open Access 01-12-2024 | Pancreatic Cancer | OriginalPaper

    Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication

    The advent of immunotherapy marks a transformative epoch in cancer treatment, yielding unprecedented clinical advantages for patients [ 1 ]. Nevertheless, limited response rates and the inability to predict clinical efficacy obstacle their further …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.